Assembly Biosciences, Inc. (ASMB)

Assembly Biosciences' stock price has been impacted by several events over the past six months. The stock price increased by 153.55% over the last 12 months, with a year-to-date return of -19.11%, and increased by 5.93% in the past month. In December 2025, Gilead Sciences Inc. exercised its option to license Assembly Biosciences' helicase-primase inhibitor programs for recurrent genital herpes, resulting in a net $35 million option fee. Positive interim Phase 1b results for ABI-1179 and ABI-5366 were reported in December 2025, showing significant reductions in viral shedding rate and genital lesion rate in recurrent genital herpes. In November 2025, Assembly Biosciences reported positive Phase 1b data for its next-generation capsid assembly modulator ABI-4334 at AASLD The Liver Meeting®. Gilead declined to exercise its option on ABI-4334, leading Assembly Biosciences to seek a new partner for the program. The company reported its year-end 2025 financial results and recent highlights in March 2026, and third-quarter 2025 financial results in November 2025. On March 18, 2026, ASMB reported an EPS of $2.48 and revenue of $42.47 million for Q4 2025, beating expectations.

Information regarding specific demand seasonality for Assembly Biosciences, Inc.'s products and services is not explicitly detailed in the provided search results. Data on ASMB seasonality, including mean and median monthly returns to identify seasonal patterns, is available through a subscription service, suggesting that while seasonal patterns might exist, specific details are not publicly accessible in the provided snippets.

Assembly Biosciences, Inc. is a clinical-stage biotechnology company focused on discovering and developing novel small molecule antiviral therapeutics for serious viral diseases within the Healthcare sector, specifically in the Biotechnology and Pharmaceuticals industries. The company's pipeline includes investigational therapies for Hepatitis B Virus (HBV) infection, Recurrent Genital Herpes, Hepatitis Delta Virus (HDV) infection, and Transplant-associated herpesviruses. Assembly Biosciences also explores small molecule strategies for HBV and HDV and is advancing a novel class of oral synthetic live biotherapeutics designed to restore health to a dysbiotic microbiome.

Assembly Biosciences, Inc. is headquartered in South San Francisco, California, United States, and develops therapeutic candidates for the treatment of viral diseases worldwide.

Assembly Biosciences' brand reputation has likely been positively influenced by the successful licensing of its helicase-primase inhibitor programs to Gilead Sciences, Inc., following positive Phase 1b interim data for ABI-5366 and ABI-1179, which validated the company's scientific strength and execution. The positive interim results from its clinical studies also contribute to a favorable reputation by demonstrating progress in addressing serious viral diseases. While Gilead's decision to decline its option on ABI-4334 could be seen as a setback, the company's proactive approach to finding a new partner for the program indicates continued commitment to its pipeline.

Assembly Biosciences, Inc. has a significant institutional ownership presence, with 66 to 74 institutional owners and shareholders holding a total of 13.39 million to 13.67 million shares as of December 2025. Institutional investors collectively increased their stake to 104.8% in December 2025, up from 100.4% in September 2025. Major institutional and individual owners include Gilead Sciences Inc., Farallon Capital Management Llc, Ra Capital Management, L.p., Commodore Capital LP, Janus Henderson Group Plc, Paradigm Biocapital Advisors LP, Point72 Asset Management, L.P., Vanguard Group Inc, Blackstone Group Inc, and Parkman Healthcare Partners LLC. Insiders hold 47.19% of the stock, with Gilead Sciences Inc., Ecor1 Capital Fund Qualified LP, Alexander Schornstein, Adam Zlotnick, and Derek A. Small listed as major insider shareholders.